Cardiol Therapeutics Inc.
corporate_fare Company Profile
Cardiol Therapeutics Inc. (NASDAQ:CRDL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for CRDL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-23, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 8/10, with 7 rated 8 or above. Recent SEC coverage for CRDL spans 6-K, 40-F.
Recent high-impact activity:
- Cardiol Hits Phase III MAVERIC Enrollment Target Early, Expands Trial to 150 Patients
- Cardiol Therapeutics' Phase II Pericarditis Data Published in JAHA; Phase III Enrollment Nears Completion
- Cardiol Therapeutics Reports Q1 2026 Results, $27.7M Cash, and Extends Runway into Q4 2027
- Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in Journal of American Heart Association
- Cardiol Therapeutics Expands Phase III MAVERIC Trial Network, Reaches 75% Patient Enrollment
Financial Snapshot
Short Interest & Short Volume
2.20 days to coverFINRA reported short interest of 3,312,998 shares in CRDL as of the September 15, 2026 settlement, a 13.2% increase from the prior period — about 2.2 days to cover at its recent average daily volume. On October 2, 2026, 27.1% of CRDL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CRDL, detected from its recent SEC filings · based on capital-structure filings through 2026-09-10.
US$150M Universal Shelf Registered · No Immediate Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
CRDL files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.